North China Pharmaceutical (600812.SH) released an announcement.
According to Zhitong Finance APP, North China Pharmaceutical (600812.SH) announced that on December 12, 2024, the company and its subsidiary, North China Pharmaceutical Group Xiantai Pharmaceutical Co., Ltd. (referred to as 'Xiantai Company'), participated in the bidding organized by the National Organization for Pharmaceutical Joint Procurement Office for the tenth batch of national centralized pharmaceutical procurement. Some pharmaceutical products from the company and Xiantai Company are intended to be selected in this centralized procurement, with the announcement period for the proposed selection from December 13, 2024, to December 16, 2024.
For this tenth batch of national centralized pharmaceutical procurement that the company and Xiantai Company participated in, all four varieties are intended to be selected. The proposed selection price of the selected products has decreased to some extent compared to the original selling price. If the selected products are confirmed, a purchase and sales contract is signed, and implementation occurs, the company will fully ensure the supply of related products according to the demand in the selected areas, promote the increase of related products in the selected areas and the development of off-market, while also intensifying efforts in new product research and market development to promote the company's long-term growth.
